Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain

Frontiers in Neuroenergetics

Volumn , Issue MAR, 2013, Pages

  Gejl, Michael ^a   Lerche, Susanne ^a   Egefjord, Lærke ^a   Brock, Birgitte ^a,b   Møller, Niels ^b   Vang, Kim ^b   Rodell, Anders B ^b   Bibby, Bo M ^a   Holst, Jens J ^c   Rungby, Jørgen ^a   Gjedde, Albert ^b,c,d,e  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Blood brain barrier; Cerebral glucose transport; Cerebral metabolic rate for glucose; Glucagon like peptide 1; Hyperglycemia; Hypoglycemia; Michaelis menten

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; HEXOKINASE; HYDROCORTISONE;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN STEM; CEREBELLUM; CEREBELLUM CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GRAY MATTER; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPOGLYCEMIA; MALE; MICHAELIS CONSTANT; MICHAELIS MENTEN KINETICS; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; THALAMUS; WHITE MATTER;

EID: 84884278554     PISSN: None     EISSN: 16626427     Source Type: Journal    
DOI: 10.3389/fnene.2013.00002     Document Type: Article

References (44)

1. Ahren, B., Schweizer, A., Dejager, S., Dunning, B. E., Nilsson, P. M., Persson, M., et al. (2009). Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 94, 1236-1243.
2. Bak, A. M., Egefjord, L., Gejl, M., Steffensen, C., Stecher, C. W., Smidt, K., et al. (2011). Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes. Expert Opin. Ther. Targets 15, 1153-1162.
3. Bingham, E. M., Dunn, J. T., Smith, D., Sutcliffe-Goulden, J., Reed, L. J., Marsden, P. K., et al. (2005). Differential changes in brain glucose metabolism during hypoglycaemia accompany loss of hypoglycaemia awareness in men with type 1 diabetes mellitus. An [11C]-3-O-methyl-D-glucose PET study. Diabetologia 48, 2080-2089.
4. Blomqvist, G., Gjedde, A., Gutniak, M., Grill, V., Widen, L., Stone-Elander, S., et al. (1991). Facilitated transport of glucose from blood to brain in man and the effect of moderate hypoglycaemia on cerebral glucose utilization. Eur. J. Nucl. Med. 18, 834-837.
5. Boyle, P. J., Nagy, R. J., O'Connor, A. M., Kempers, S. F., Yeo, R. A., and Qualls, C. (1994). Adaptation in brain glucose uptake following recurrent hypoglycemia. Proc. Natl. Acad. Sci. U.S.A. 91, 9352-9356.
6. Crone, C. (1965). Facilitated transfer of glucose from blood into brain tissue. J. Physiol. 181, 103-113.
7. Cryer, P. E. (2004). Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N. Engl. J. Med. 350, 2272-2279.
8. Cura, A. J., and Carruthers, A. (2012). AMP kinase regulation of sugar transport in brain capillary endothelial cells during acute metabolic stress. Am. J. Physiol. Cell Physiol. 303, C806-C814.
9. D'Alessio, D. A., Sandoval, D. A., and Seeley, R. J. (2005). New ways in which GLP-1 can regulate glucose homeostasis. J. Clin. Invest. 115, 3406-3408.
10. Degn, K. B., Brock, B., Juhl, C. B., Djurhuus, C. B., Grubert, J., Kim, D., et al. (2004). Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53, 2397-2403.
11. Gejl, M., Egefjord, L., Lerche, S., Vang, K., Bibby, B. M., Holst, J. J., et al. (2012a). Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. J. Cereb. Blood Flow Metab. 32, 2146-2152.
12. Gejl, M., Sondergaard, H. M., Stecher, C., Bibby, B. M., Moller, N., Botker, H. E., et al. (2012b). Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 97, E1165-E1169.
13. Gjedde, A. (1981). High- and low-affinity transport of D-glucose from blood to brain. J. Neurochem. 36, 1463-1471.
14. Gjedde, A. (1982). Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 257, 237-274.
15. Gjedde, A. (1983). Modulation of substrate transport to the brain. Acta Neurol. Scand. 67, 3-25.
16. Gjedde, A., and Christensen, O. (1984). Estimates of Michaelis-Menten constants for the two membranes of the brain endothelium. J. Cereb. Blood Flow Metab. 4, 241-249.
17. Gjedde, A., and Crone, C. (1981). Blood-brain glucose transfer: repression in chronic hyper-glycemia. Science 214, 456-457.
18. Gjedde, A., Wienhard, K., Heiss, W. D., Kloster, G., Diemer, N. H., Herholz, K., et al. (1985). Comparative regional analysis of 2-fluorodeoxyglucose and methylglucose uptake in brain of four stroke patients. With special reference to the regional estimation of the lumped constant. J. Cereb. Blood Flow Metab. 5, 163-178.
19. Grieve, D. J., Cassidy, R. S., and Green, B. D. (2009). Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br. J. Pharmacol. 157, 1340-1351.
20. Hasselbalch, S. G., Knudsen, G. M., Capaldo, B., Postiglione, A., and Paulson, O. B. (2001). Blood-brain barrier transport and brain metabolism of glucose during acute hyperglycemia in humans. J. Clin. Endocrinol. Metab. 86, 1986-1990.
21. Hasselbalch, S. G., Knudsen, G. M., Videbaek, C., Pinborg, L. H., Schmidt, J. F., Holm, S., et al. (1999). No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 48, 1915-1921.
22. Hasselbalch, S. G., Madsen, P. L., Knudsen, G. M., Holm, S., and Paulson, O. B. (1998). Calculation of the FDG lumped constant by simultaneous measurements of global glucose and FDG metabolism in humans. J. Cereb. Blood Flow Metab. 18, 154-160.
23. Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409-1439.
24. Holst, J. J., Burcelin, R., and Nathanson, E. (2011). Neuroprotective properties of GLP-1: theoretical and practical applications. Curr. Med. Res. Opin. 27, 547-558.
25. Hou, J., Manaenko, A., Hakon, J., Hansen-Schwartz, J., Tang, J., and Zhang, J. H. (2012). Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 32, 2201-2210.
26. Jensen, M. G., Hansen, M., Brock, B., and Rungby, J. (2010). Differences between long-acting insulins for the treatment of type 2 diabetes. Expert Opin. Pharmacother. 11, 2027-2035.
27. Kennan, R. P., Takahashi, K., Pan, C., Shamoon, H., and Pan, J. W. (2005). Human cerebral blood flow and metabolism in acute insulin-induced hypoglycemia. J. Cereb. Blood Flow Metab. 25, 527-534.
28. Kuwabara, H., Evans, A. C., and Gjedde, A. (1990). Michaelis-Menten constraints improved cerebral glucose metabolism and regional lumped constant measurements with [18F]fluorodeoxyglucose. J. Cereb. Blood Flow Metab. 10, 180-189.
29. Lerche, S., Brock, B., Rungby, J., Botker, H. E., Moller, N., Rodell, A., et al. (2008). Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes 57, 325-331.
30. Leybaert, L. (2005). Neurobarrier coupling in the brain: a partner of neurovascular and neurometabolic coupling? J. Cereb. Blood Flow Metab. 25, 2-16.
31. Maran, A., Lomas, J., Macdonald, I. A., and Amiel, S. A. (1995). Lack of preservation of higher brain function during hypoglycaemia in patients with intensively-treated IDDM. Diabetologia 38, 1412-1418.
32. Mathiisen, T. M., Lehre, K. P., Danbolt, N. C., and Ottersen, O. P. (2010). The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 58, 1094-1103.
33. McCall, A. L. (2004). Cerebral glucose metabolism in diabetes mellitus. Eur. J. Pharmacol. 490, 147-158.
34. Michaelis, L., and Menten, M. L. (1913). Die kinetik der invertinwirkung. Biochem. Z 49, 333-369.
35. Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., et al. (2002). Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 87, 1239-1246.
36. Pardridge, W. M. (1983). Brain metabolism: a perspective from the blood-brain barrier. Physiol. Rev. 63, 1481-1535.
37. Poulsen, P. L., Orskov, L., Grofte, T., Moller, J., Holst, J. J., Schmitz, O., et al. (2000). Effects of oral glucose on systemic glucose metabolism during hyperinsulinemic hypoglycemia in normal man. Metab. Clin. Exp. 49, 1598-1603.
38. Ronnett, G. V., Ramamurthy, S., Kleman, A. M., Landree, L. E., and Aja, S. (2009). AMPK in the brain: its roles in energy balance and neuroprotection. J. Neurochem. 109(Suppl. 1), 17-23.
39. Segel, S. A., Fanelli, C. G., Dence, C. S., Markham, J., Videen, T. O., Paramore, D. S., et al. (2001). Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes 50, 1911-1917.
40. Simpson, I. A., Carruthers, A., and Vannucci, S. J. (2007). Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J. Cereb. Blood Flow Metab. 27, 1766-1791.
41. Toft-Nielsen, M. B., Madsbad, S., and Holst, J. J. (1999). Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22, 1137-1143.
42. UKPDS. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853.
43. Vella, A., and Rizza, R. A. (2004). Extrapancreatic effects of GIP and GLP-1. Horm. Metab. Res. 36, 830-836.
44. Wang, W. T., Lee, P., Yeh, H. W., Smirnova, I. V., and Choi, I. Y. (2012). Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin-induced diabetes detected using in vivo (1)H MR spectroscopy at 9.4 T. J. Neurochem. 121, 407-417.